Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma Cmn (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 28,088
  • Shares Outstanding, K 22,470
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,060 K
  • 36-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.09 +4.59%
on 07/21/17
1.54 -25.97%
on 06/29/17
-0.17 (-12.98%)
since 06/21/17
3-Month
1.09 +4.59%
on 07/21/17
2.05 -44.39%
on 04/25/17
-0.31 (-21.38%)
since 04/21/17
52-Week
1.08 +5.56%
on 02/01/17
7.89 -85.55%
on 09/29/16
-2.36 (-67.43%)
since 07/21/16

Most Recent Stories

More News
Sarepta Appoints Ex-Allergan Executive as CEO and President

Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).

CATB : 1.14 (-8.80%)
SRPT : 43.41 (+6.06%)
AGN : 250.97 (+0.76%)
REGN : 515.92 (-1.00%)
Catabasis Pharmaceuticals to Present Results from the MoveDMD(R) Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data from Part A and Part B of the MoveDMD trial of...

CATB : 1.14 (-8.80%)
Pre-Market Technical Recap on Biotech Stocks -- Array BioPharma, Catabasis Pharma, Cerulean Pharma, and Immunomedics

If you want a stock review on ARRY, CATB, CERU, or IMMU then come over to http://dailystocktracker.com/register/ and sign up for your free customized reports today. DailyStockTracker.com has initiated...

CATB : 1.14 (-8.80%)
ARRY : 8.24 (-1.67%)
CERU : 0.66 (+4.76%)
IMMU : 8.66 (+0.46%)
Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference

-- Data Demonstrate Improved Intracellular Clearance of Bacteria of Importance in Patients with Cystic Fibrosis --

CATB : 1.14 (-8.80%)
Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that CAT-5571, a novel activator of autophagy, will be presented as a potential...

CATB : 1.14 (-8.80%)
J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021

Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.

CATB : 1.14 (-8.80%)
VVUS : 1.24 (+1.64%)
JNJ : 135.31 (-0.92%)
PFE : 33.48 (-0.18%)
Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth

On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.

OREX : 2.47 (-5.00%)
CATB : 1.14 (-8.80%)
VVUS : 1.24 (+1.64%)
EPZM : 13.35 (+0.38%)
Catabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress

-- MoveDMD Trial Progressing, Part C Interim Results Expected in Q3 2017 --

CATB : 1.14 (-8.80%)
Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 11, 2017 / Catabasis Pharmaceuticals Inc (NASDAQ: CATB) will be discussing their earnings results in their Q1 Earnings Call to be held May 11, 2017 at 4:30 PM Eastern Time....

CATB : 1.14 (-8.80%)
Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde

Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 22 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents. The company had reported a loss...

ENZ : 11.35 (-1.05%)
CATB : 1.14 (-8.80%)
SHPG : 164.03 (+2.38%)
MACK : 1.29 (-0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Support & Resistance

2nd Resistance Point 1.37
1st Resistance Point 1.26
Last Price 1.14
1st Support Level 1.06
2nd Support Level 0.97

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.